Skip to content

Obsidian® ASG Autologous Platelet-Rich Fibrin Matrix for the prevention of postoperative pancreatic fistula following pancreatic resection – A feasibility pilot trial

Obsidian® ASG Autologous Platelet-Rich Fibrin Matrix for the prevention of postoperative pancreatic fistula following pancreatic resection – A feasibility pilot trial - Obsidian - pilot trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00034052
Enrollment
25
Registered
2024-05-06
Start date
2026-01-09
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

complications after partial pancreatectomy

Interventions

Group 1: Patients scheduled for elective formal partial pancreatectomy due to any underlying disease will be included according to the eligibility criteria. Obsidian® ASG sealant prepared out of 120mL

Sponsors

Medizinische Universität Wien
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Scheduled for elektive partial pancreatic resection, due to any underlying disease.

Exclusion criteria

Exclusion criteria: Inclusion criteria comprise =18 years of age, ability to understand character and individual consequences of the clinical trial, as well as written informed consent. For patients with childbearing potential, presence of preoperative negative urine or negative blood pregnancy test and adequate contraception until 14 days after trial intervention is required. Patients with severe systemic disease that is a constant threat to life, classified as American Society of Anaesthesiologists’ (ASA) score >3 and patients with known hypersensitivity to any component in the formulation will be excluded as will be patients with understanding or language problems and patients with inability to comply with the study and/or follow-up procedures. Pregnant and breast-feeding patients as well as patients with concurrent participation in another interventional clinical trial with interference with the trial outcome will also be excluded.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the feasibility of the procedure, e.g. proportion of patients undergoing successful trial intervention.

Secondary

MeasureTime frame
Secondary endpoints comprise safety and surgical outcome parameters including rate and severity of POPF as well as further pancreas-specific complications as defined by the International Study Group of Pancreatic Surgery (ISGPS) during 90 days after surgery.

Countries

Austria

Contacts

Public ContactUlla Klaiber

Medizinische Universität Wien

ulla.klaiber@meduniwien.ac.at004314040069100

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026